AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05885997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported HBPM program plus multifaceted implementation strategy
Description: Supported HBPM Program:~* Patients are loaned a wireless home BP device or use their own device~* Navigator or app support for onboarding and engaging patients in HBPM~* Nursing or app support for monitoring and triaging home BP data for extreme readings~* EHR integration of order for program and home BP data, with weekly feedback of home BP results to clinicians within the EHR~Multifaceted implementation strategy:~* Clinician education about the benefits of the program as well as training in how to refer and manage patients who are enrolled~* Prompts and reminders to increase clinician referrals~* Instructional materials for patients and clinicians~* Problem-solving meetings to tailor implementation for individual practices
Study NCT05192369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: CTP-543 12 mg (1 x 12 mg tablet), dosed with water
Study NCT05192369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: CTP-543 48 mg (4 x 12 mg tablet) dosed with water
Study NCT05087992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab
Study NCT05885997 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study NCT05192369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin (1 x 400 mg tablet) dosed with water
Study NCT05885997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care
Study NCT05192369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1 tablet) dosed with water
Study NCT05443204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortimel energy
Description: Standard nutritional oral supplement
Study NCT05443204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrision Advanced Diason Energy HP
Description: Specifc nutritional oral supplement in diabetics patients
Study NCT04918823 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Restasis
Description: Subject will use one drop of Restasis in the lens before insertion
Study NCT05090124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.
Study NCT05090124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.
Study NCT05349500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OA CARE Intervention
Description: Once assigned, participants will be contacted by the OA CARE Navigator to coordinate initiating a YMCA Medical Membership. Then, YMCA personnel will contact the participant to schedule the first Weight Loss Program (Program) group session. The Program will be delivered in groups with other OA CARE participants. Participants will also have access to all exercise facilities and programs at the YMCA during the study, and will be assigned a YMCA health coach.~After initiation of the YMCA Medical Membership, the OA CARE Navigator will discuss participant's interests in referrals to other services related to osteoarthritis (OA) management. The Navigator will provide the participant's primary care provider (PCP) with a summary of this discussion and help the participant connect to any programs or resources that do not require provider referrals.
Study NCT05349500 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care control group
Description: Participants assigned to the usual care group will receive no additional treatment from the study for about 12 months. However, this group will be offered a 12-month Medical Membership to a local YMCA after completing the final assessment.
Study NCT06414018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: alfentanil 10ug/kg is used for anesthesia induction
Study NCT06115499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Given IV
Study NCT06115499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Given IV
Study NCT06115499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT06115499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study NCT06115499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT06115499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04478825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S
Description: BBT-401-1S, 8 weeks, once a day
Study NCT04992975 — intervention group
Intervention type: OTHER
Intervention: MRI at 7T
Description: MRI at 7T
Study NCT06115499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06115499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06115499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06115499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06115499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05272865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
Description: Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.
Study NCT05272865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
Description: Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.
Study NCT06257030 — intervention group
Intervention type: DEVICE
Intervention: Transarterial Radioembolization
Description: (TARE)Transarterial radioembolization is a transcatheter intra-arterial procedure performed by the interventional radiologist for the treatment of primary and secondary hepatic cancers.
Study NCT06433245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: effect of 3% and 5% sodium hypochlorite on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.
Description: After caries removal and pulp exposure pulp tissue is amputated and hemostasis is achieved with 3% sodium hypochlorite in control group and 5% sodium hypochlorite in experimental group followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
Study NCT06433245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: effect of 3% and 5% sodium hypochlorite on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.
Description: After caries removal and pulp exposure pulp tissue is amputated and hemostasis is achieved with 3% sodium hypochlorite in control group and 5% sodium hypochlorite in experimental group followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
Study NCT05558150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg
Study NCT05558150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100mg
Study NCT05718986 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05467722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Single 12 mg oral dose administered on Day 1
Study NCT04497025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive Virtual-based vestibular rehabilitation
Description: Vestibular rehabilitation based on virtual environment using a head mounted display
Study NCT04497025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vestibular rehabilitation protocol
Description: Cawthorne-Cooksey vestibular rehabilitation exercises.
Study NCT04812626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Group A: 1ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline Group B:1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU Five units (0.125ml) of the mixture TAC 40mg/ml and 5-FU 50mg/ml (1:1) i.e. 2.5mg TAC and 3.125mg of 5-FU or TAC 40mg/ml and 2%xylocaine (1:1) i.e. 2.5mg of TAC will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, thus, a scar of 1 cm2 will require 4 injections to cover the whole lesion. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. For the larger lesions, dose can be increased but no more than 2ml in each group. Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
Study NCT04812652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally distributed yoga
Description: Yoga distributed through internet.
Study NCT06539546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yttria stabilized multilayered (YML) zirconia restorations
Description: Yttria stabilized multilayered zirconia restorations were claimed to have high strength and esthetics at the same time but no clinical studies were conducted yet to prove its high esthetic properties
Study NCT06539546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lithium disilicate restorations
Description: Lithium disilicate reinforced glass ceramics are considered a gold standard for monolithic esthetic restorations.
Study NCT06519123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Digital Scribes
Description: AI technology used to populate clinical notes.
Study NCT06335056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ProudMe
Description: ProudMe Tech: Regular human/computer interaction (3-5 times per week) to engage in SMART goal-setting, behavior monitoring, and self-reflection as assisted by AI-enabled feedback.~ProudMe Physical Education \[PE\]: 12 lessons to acquire knowledge, skill, and dispositions to improve physical activity, diet, screen-based sedentary behaviors.~ProudMe Cafeteria: Purposely enabling policy and environmental changes in school cafeteria (recognize areas of strengths and weaknesses; set goals and action plans; make changes to improve scores assessed by the Smarter Lunchroom Scorecard).~ProudMe Training: 4-hour implementation training + regular check-in and support (via motivational interviewing techniques)
Study NCT06335056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: The waitlist control involves (a) regular physical/health education and lunchroom, (b) professional development training on the overall importance of quality physical/health education, health eating and foot environment. It does not involve AI-assisted behavior management system.
Study NCT04834869 — intervention group
Intervention type: BIOLOGICAL
Intervention: BNT162b2
Description: Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)
Study NCT04834869 — intervention group
Intervention type: BIOLOGICAL
Intervention: mRNA-1273
Description: Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)
Study NCT04834869 — intervention group
Intervention type: BIOLOGICAL
Intervention: AZD1222
Description: Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)
Study NCT04834869 — intervention group
Intervention type: BIOLOGICAL
Intervention: CoronaVac
Description: Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)
Study NCT04834869 — intervention group
Intervention type: BIOLOGICAL
Intervention: Sinopharm
Description: Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine
Study NCT04834869 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gam-COVID-Vac
Description: Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)
Study NCT04834869 — intervention group
Intervention type: BIOLOGICAL
Intervention: JNJ-78436735
Description: Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)
Study NCT04834869 — intervention group
Intervention type: BIOLOGICAL
Intervention: CVnCoV
Description: Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)
Study NCT04834869 — intervention group
Intervention type: BIOLOGICAL
Intervention: NVX-CoV2373
Description: Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)
Study NCT04834869 — intervention group
Intervention type: BIOLOGICAL
Intervention: BBV152
Description: Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)
Study NCT05321784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Description: Take digital dermoscopy images (DDI)
Study NCT05321784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Photography
Description: Take smartphone clinical images (SCI)
Study NCT05321784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-Skin Examination
Description: Perform self-skin exam (SSE)
Study NCT05321784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Examination with Sklip
Description: Apply Sklip System
Study NCT05321784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Examination
Description: Undergo in-person full body skin examination (FBSE)
Study NCT05321784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06087835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan/Dapagliflozin
Description: Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
Study NCT06087835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin as per the arms they are randomized to
Study NCT04915040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Depression
Description: Behavioral Activation (BA) is an effective treatment for depression, and its components may increase social connection. Generally, caregivers are with the older adult care recipient on a regular basis and may be able, with the correct training, to help enhance certain features of the Behavioral Activation treatment, even under pandemic restrictions on social contact. Therefore, we propose to (a) integrate \& (b) gather feasibility data for home-based Behavioral Activation + Caregiver
Study NCT06103903 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire according to age (6-13;14-17); the parents for minors and adults
Study NCT06375993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-001
Description: Anti-CD20 CAR-T
Study NCT06375993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for Lymphodepletion
Study NCT06375993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for Lymphodepletion
Study NCT05937672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
Description: The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
Study NCT05192811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei K56
Description: probiotic K56 capsule, 1capsule/day (10\^9cfu) ,for 60days
Study NCT05192811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule(maltodextrin) , 1capsule/day ,for 60days
Study NCT05149521 — intervention group
Intervention type: OTHER
Intervention: None - this is a consensus group study to develop an intervention
Description: None - this is a consensus group study to develop an intervention
Study NCT06063083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell Me More (Dime Mas)
Description: Participants will receive an initial approximately 1 hour outreach session followed by up to 3 approximately monthly check-in outreach attempts (approximately 15 minutes each). All study visits can be done in person or remotely. Each contact will involve helping participants get connected to PrEP, HIV testing, and behavioral health treatment.
Study NCT06063083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Ambassador Stories [Listen Miami (Oye Miami)]
Description: Participants will receive a link to a website featuring stories of local Latino MSM using PrEP, HIV testing, and behavioral health treatments. Participants will receive intermittent (based on personal choice) reminders to view the website. The website will also show referrals to services and provide the option to submit a story via written, video, or audio recording. Participants can access the website using a personal electronic device at any time during within the study period.
Study NCT06063083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Community Outreach
Description: Participants will receive the standard community outreach, which will be a list of referrals for HIV testing, PrEP, and behavioral health treatments.
Study NCT06063083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Community Outreach
Description: Participants will receive the standard community outreach, which will be a list of referrals for HIV testing, PrEP, and behavioral health treatments.
Study NCT06456762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iPEACE: Intervention for Parent Education about Care after the ED
Description: Automated texting intervention for parents to increase engagement in their child's outpatient mental health treatment over an 8-week period.
Study NCT06456762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging Reminders Only
Description: Weekly automated text reminders to instruct parents to make an appointment with their child's outpatient mental health provider over an 8-week period.
Study NCT06360627 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Computed Tomography
Description: Computed Tomography CHEST
Study NCT03657056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BX Pulsar 1002
Description: LIFUP will be administered to the temporal region on the side to undergo surgery, within the focus producing seizures. The ultrasound will be focused on the highest activity area within the temporal lobe. Functional MRI of the brain will be obtained throughout the LIFUP session.~After the participant is fitted with the transducer they will be placed in the MRI machine and undergo a series of scans. After placing the transducer over the anterior tip of the temporal lobe the participant will undergo fMRI BOLD scans with LIFUP excitation (from (Lee et al., 2015): Tone Burst Duration = 2ms and Pulse Repetition Frequency = 250Hz) at four levels of intensity (720mW/cm2, 1440mW/cm2, 2880mW/cm2 and 5760mW/cm2). Before increasing the intensity, the transducer will be moved approximately 5mm posterior. After the last excitation scan the LIFUP parameters will be changed to inhibitory parameters (from (Yoo et al., 2011): Tone Burst Duration = 0.5ms and Pulse Repetition Frequency = 100Hz).
Study NCT05742555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention
Description: After the relatives of the patients included in the experimental group are informed about the study, they will be asked to fill in the Participant Information Form, Nottingham Health Profile (NSP) and Warwick-Edinburgh Mental Well-Being Scale (WEMIOÖ) after obtaining their permission. The virtual reality intervention will be applied to the caregivers at a suitable time of the day (when the patient's care and treatment is not intensive, the caregiver wishes). Different nature scenes (sea, forest, stream) with different types of music (classical music, nature sounds, relaxing music) will be watched for 10 minutes, 3 days a week. The application will be made for 4 weeks. At the end of this period, they will be asked to fill the NSP and WEMİOÖ again as a final test.